Products for Research Use Only
RegisterLogin

Samuraciclib (hydrochloride hydrate)

CAT: 0804-HY-103712C-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-103712C-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects[1][2].
Product Name Alternative
CT7001 (hydrochloride hydrate) ; ICEC0942 (hydrochloride hydrate)
UNSPSC
12352005
Target
Apoptosis; CDK
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/samuraciclib-hydrochloride-hydrate.html
Purity
99.88
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O[C@H]1CNCC[C@@H]1CNC2=NC3=C(C(C)C)C=NN3C(NCC4=CC=CC=C4)=C2.Cl.O
Molecular Formula
C22H30N6O. (2.5HCl) . (3.7H2O)
Molecular Weight
552.33
References & Citations
[1]Patel H, et al. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. Mol Cancer Ther. 2018 Jun;17 (6) :1156-1166.|[2]Hazel P, et al. Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study. ChemMedChem. 2017 Mar 7;12 (5) :372-380.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CDK1; CDK2; CDK4; CDK5; CDK6; CDK7; CDK9
Citation 01
EMBO J. 2025 Sep 8.|Adv Sci (Weinh) . 2024 Dec 10:e2413103.|Biochem Biophys Res Commun. 2024 Aug 28:735:150608.|Cell Death Dis. 2019 Aug 9;10 (8) :602.|Clin Cancer Res. 2024 May 1;30 (9) :1889-1905.|Proc Natl Acad Sci U S A. 2019 Jun 25;116 (26) :12986-12995. |Res Sq. 2024 Jul 29.|Structure. 2024 Jun 9:S0969-2126 (24) 00188-6.|Int J Mol Sci. 2022 Feb 24;23 (5) :2493.|J Cancer Res Clin Oncol. 2023 Jul;149 (8) :5255-5263.|mBio. 2025 Dec 10;16 (12) :e0289825.|Signal Transduct Target Ther. 2025 Nov 6;10 (1) :363.

Related Products

CatalogName
HY-103712A-01Samuraciclib (hydrochloride)
HY-103712B-01Samuraciclib (hydrochloride dihydrate)
HY-103712-01Samuraciclib
HY-W040074-01Glycylglycine (hydrochloride hydrate)
HY-147056APKRA83 (hydrochloride hydrate)
HY-D0907Beth hydrochloride hydrate
HY-120081A-01Metixene (hydrochloride hydrate)
HY-13567ABendamustine (hydrochloride hydrate)
HY-17382A-01Metoclopramide (hydrochloride hydrate)
HY-14792CInolitazone (hydrochloride hydrate)

Alternative Products

CatalogName
T63650-01Samuraciclib hydrochloride hydrate
GTR19176852-01Samuraciclib hydrochloride
C13616-5mgSamuraciclib (ICEC0942) hydrochloride
C5039-5000Quinacrine (hydrochloride hydrate)
A9916-100Fedratinib hydrochloride hydrate
B8793-10(−)-Apomorphine (hydrochloride hydrate)
FA61507-01Metoclopramide hydrochloride hydrate
FA34819Adenine hydrochloride hydrate
T4548-01Procaterol hydrochloride hydrate
TSH-00329-01TETA hydrochloride hydrate

Popular Products